Ibogaine Research: A Long History

The Bwiti spiritual tradition of the Mitsogo and Apindji peoples of what is now Gabon centers on the root bark of Tabernanthe iboga as a sacrament. Initiates consume iboga root in multi-day ceremonies to commune with ancestors, confront death, and receive guidance for life. The Bwiti understanding of iboga, as a medicine that dissolves ego, reveals truth, and heals, predates Western science by centuries. Everything that follows in this timeline builds on what they already knew.

Fernandez JW (1982). Bwiti: An Ethnography of the Religious Imagination in Africa. Princeton University Press.

Bwiti practice gradually spread from the Mitsogo to neighboring peoples across the forests of present-day Gabon, Cameroon, and the Republic of Congo. The ceremonies evolved as they moved between cultures, with each community developing its own relationship with the plant. By the time European explorers arrived in the 19th century, iboga ceremonial use was deeply embedded across the region, a living pharmacological tradition that had been refined over centuries.

Fernandez JW (1982). Bwiti: An Ethnography of the Religious Imagination in Africa.

French colonial officer Mézard produced one of the earliest documented European accounts of iboga use among Gabonese peoples, describing ceremonial consumption of the root bark and its effects on participants. The account marked the beginning of Western documentation of a practice that had already existed for centuries.

⚠ Citation pending verification. Will be confirmed before publication

Cited in ethnobotanical literature on iboga history: citation pending verification

American missionary Reverend William Walker provided an early Protestant-era account of iboga use among communities in Gabon, documenting the plant's ceremonial role and effects. Missionary records from this period form an important, if culturally biased, layer of early Western documentation of the Bwiti tradition.

⚠ Citation pending verification. Will be confirmed before publication

Mission records, Gabon, 1856: citation pending verification

French naval surgeon Griffon du Bellay produced the first Western botanical description of Tabernanthe iboga, documenting the plant's physical characteristics and its use by local peoples in Gabon. His account established iboga as a distinct botanical entity in European scientific literature and set the stage for later chemical investigation.

⚠ Citation pending verification. Will be confirmed before publication

Comptes Rendus de l'Académie des Sciences: citation pending exact volume verification

French botanist Henri Ernest Baillon formally classified the plant as Tabernanthe iboga within the Apocynaceae family, giving it the scientific name that researchers would use going forward. The classification gave iboga a stable scientific identity and made its chemistry accessible to the European pharmacological establishment.

Bulletin de la Société Linnéenne de Paris (1889)

Working in France, pharmacologists J. Dybowski and E. Landrin isolated ibogaine as a distinct alkaloid from the root bark of Tabernanthe iboga. Their chemical work established ibogaine as a compound with its own identity, separate from the plant, and opened the door to pharmaceutical research. It was the first time the active molecule had been purified, characterized, and named.

Comptes Rendus de l'Académie des Sciences, 1901

French researchers Haller and Heckel followed up on the 1901 isolation with further chemical characterization of ibogaine, clarifying its properties and documenting its stimulant effects on the nervous system. Their work extended the pharmacological profile beyond simple isolation and helped establish ibogaine as a compound of potential clinical interest.

⚠ Citation pending verification. Will be confirmed before publication

Journal de Pharmacie et de Chimie (1905): citation pending exact volume verification

Laboratoires Lafon, a French pharmaceutical company, began marketing ibogaine hydrochloride (8mg per tablet) under the brand name Lambarène, named for the Gabonese city near where iboga was harvested. Sold over the counter as a neuromuscular stimulant and anti-fatigue agent, it was reportedly used by Tour de France cyclists, soldiers, and laborers across France. The product remained on the market for roughly 25 years before being withdrawn in 1966 as ibogaine's more powerful psychoactive profile came to be better understood.

Alper KR (2001). Ibogaine: A Review. In: Alkaloids: Chemistry and Biology, Vol. 56. Academic Press.

Pharmacologist Harris Isbell at the National Institute of Mental Health's Addiction Research Center in Lexington, Kentucky conducted one of the first controlled pharmacological studies of ibogaine in humans. The study formally characterized ibogaine's central nervous system effects and psychoactive properties in a clinical context, the first time these had been systematically documented rather than anecdotally reported.

NIMH Addiction Research Center, Lexington, KY (1955)

The full three-dimensional molecular structure of ibogaine was confirmed through X-ray crystallography. This structural knowledge underpinned decades of subsequent pharmacological research and eventually made it possible to design synthetic analogues, molecules that replicate ibogaine's therapeutic mechanisms while modifying its duration, psychoactivity, or cardiac safety profile.

Janot et al. (1957): structural confirmation

After roughly 25 years as an over-the-counter product, Lambarène was withdrawn from French pharmacies as regulators came to better understand ibogaine's potent psychoactive profile. The withdrawal ended the pharmaceutical era of ibogaine in Western medicine, until the addiction research of the 1990s brought it back into clinical focus.

Historical pharmaceutical record (France)

Howard Lotsof, a 19-year-old heroin-dependent student in New York, took ibogaine expecting a psychedelic experience. Instead, he emerged 36 hours later to find his craving for heroin had vanished, and stayed gone. He was the first person to recognize and document this effect. Lotsof spent the rest of his life fighting to have ibogaine studied as an addiction treatment. Everything that has happened in ibogaine research since traces back to this moment.

Documented in Alper KR et al. (1999) and in Lotsof's own published accounts

After recognizing ibogaine's anti-addiction potential in himself, Howard Lotsof facilitated ibogaine treatments for seven people with various substance dependencies in the Netherlands. Five of the seven reported stopping drug use after the experience. This informal series, while not a controlled study, was the earliest human evidence that ibogaine's anti-addiction effect extended beyond a single case, and it launched Lotsof's two-decade campaign to get the compound formally studied.

⚠ Citation pending verification. Will be confirmed before publication

Cited in Alper KR et al. (1999): primary accounts pending verification

Howard Lotsof was granted US Patent 4,499,096 for the use of ibogaine in the treatment of opioid dependence, the first patent ever filed for ibogaine as a medical treatment. He followed this with additional patents covering stimulant, alcohol, and nicotine dependence. The patents were his mechanism for protecting the idea long enough to see it formally studied, and they attracted the attention of pharmaceutical researchers and eventually the US National Institute on Drug Abuse.

Nico Adriaans and the Dutch harm reduction organization Streetcornerwork established the first systematic underground ibogaine treatment network in the Netherlands. Working outside clinical settings but with careful protocols, they treated dozens of people with heroin dependence and documented outcomes. This contributed real-world evidence that shaped the scientific research agenda that followed and demonstrated that safe ibogaine administration was possible outside hospital settings.

Documented in harm reduction and psychedelic medicine literature

The foundational paper in ibogaine preclinical research. Stanley Glick and colleagues at Albany Medical College showed that a single dose of ibogaine reduced morphine self-administration in rats, and kept it reduced for days after the drug had cleared the system. This 'aftereffect,' persisting well beyond ibogaine's half-life, became the central puzzle of the field: how does a 36-hour experience reset the brain's relationship with opioids for weeks? The paper launched a decade of mechanistic research trying to answer that question, and it gave NIDA the scientific justification it needed to fund formal research.

The US National Institute on Drug Abuse began formally funding ibogaine research, following advocacy by Howard Lotsof and the growing evidence from the Netherlands underground treatment network. This represented the first time a US federal agency took ibogaine seriously as a potential addiction treatment, and it opened the door to FDA engagement.

NIDA Research Program (1991)

The FDA approved an Investigational New Drug application filed by University of Miami researcher Deborah Mash, clearing the way for the first FDA-sanctioned clinical trials of ibogaine in humans for addiction treatment. Regulatory and liability concerns meant the trial was eventually conducted in St. Kitts rather than the United States, but the IND approval marked a turning point in ibogaine's relationship with American regulatory medicine.

FDA IND records (1993)

The first formally published case report series documenting ibogaine's effect on opioid withdrawal in a clinical setting. Seven heroin-dependent subjects received oral ibogaine doses of 700–1,800mg. By the end of the 24–38 hour psychoactive period, most reported that their withdrawal symptoms had effectively resolved. Several remained off opioids for weeks or months afterward. It is a small, uncontrolled series with all the limitations that implies, but it was the first time the phenomenon Howard Lotsof had described in 1962 appeared in a peer-reviewed medical journal, establishing a published clinical baseline for everything that followed.

Pharmacologist Stanley Glick and colleagues at Albany Medical College demonstrated that ibogaine significantly reduced morphine and cocaine self-administration in rats, in some cases by 50–90% after a single dose. The effects persisted for days after ibogaine had cleared the system. This preclinical work provided mechanistic evidence for ibogaine's anti-addiction properties and drove significant further research into how it worked at the receptor level.

Brain Research (1995)

Researchers at the FDA found evidence of Purkinje cell changes in the cerebella of rats given high doses of ibogaine. This raised a neurotoxicity concern that significantly slowed US clinical research for years. Subsequent analysis found the doses used were large multiples of the proposed human therapeutic range, and no human studies have confirmed the effect. However, the concern shaped the regulatory environment and drove interest in lower-dose protocols and synthetic analogues.

Brain Research (1996)

Deborah Mash and colleagues published the first human pharmacokinetics data for ibogaine and its primary metabolite noribogaine, based on the St. Kitts patient cohort. They established ibogaine's relatively short half-life (approximately 4–7 hours) and noribogaine's much longer half-life (28–49 hours). This suggests that noribogaine carries much of the sustained anti-craving effect that patients report lasting days or weeks after treatment.

⚠ Citation pending verification. Will be confirmed before publication

Annals of the New York Academy of Sciences (1998): year pending verification

A pivotal discovery for anyone practicing ibogaine medicine: the liver's CYP2D6 enzyme is responsible for converting ibogaine into its primary active metabolite, noribogaine. This matters enormously in clinical practice because roughly 5–10% of people of European ancestry are CYP2D6 poor metabolizers. They convert ibogaine much more slowly, resulting in substantially higher drug exposure from the same dose. The paper provided the mechanistic basis for CYP2D6 genetic screening before treatment, an approach a growing number of clinics use to guide dosing. It also explained why noribogaine (half-life 28–49 hours) outlasts ibogaine (half-life 4–7 hours) in the body, producing the extended anti-craving effect patients report lasting days or weeks after the session.

Kenneth Alper and colleagues published the first peer-reviewed clinical case series of ibogaine for opioid withdrawal, 33 patients treated in non-hospital settings across multiple sites. The majority reported significant reduction or elimination of withdrawal symptoms within 24 hours of treatment. The paper established a clinical baseline that subsequent studies would build on and remains one of the most widely cited ibogaine papers.

⚠ Citation pending verification. Will be confirmed before publication

American Journal on Addictions (1999): DOI pending verification

Kenneth Alper's comprehensive review of ibogaine pharmacology and clinical evidence synthesized everything known about ibogaine: from its chemistry through preclinical studies to human data. Published in the Alkaloids series (Academic Press), it became the standard reference for researchers entering the field and is still widely cited. Note: this is a book chapter, not a journal article. User to confirm if book chapters are in scope for this page.

Alkaloids: Chemistry and Biology, Vol. 56. Academic Press (2001)

Deborah Mash and colleagues published outcomes data from the St. Kitts observational cohort, patients treated for opioid and cocaine dependence with ibogaine. The study documented significant reductions in withdrawal severity and craving scores, with many patients reporting abstinence at 30-day follow-up. The St. Kitts program treated hundreds of patients over more than a decade and produced the largest observational dataset in early ibogaine research.

⚠ Citation pending verification. Will be confirmed before publication

Annals of the New York Academy of Sciences: exact year and volume pending verification

New Zealand researchers conducted an observational follow-up study with former heroin-dependent individuals who had received ibogaine treatment. The study found sustained reductions in heroin use and cravings at follow-up, adding to the growing international evidence base from outside formal clinical trial settings.

Journal of Psychoactive Drugs (2008)

Kenneth Alper and colleagues surveyed 41 providers within the underground ibogaine treatment subculture, documenting treatment protocols, patient populations, and outcomes across dozens of sites worldwide. The survey captured a large body of real-world evidence that would never have been generated within formal clinical channels and helped characterize ibogaine's real-world risk profile and efficacy patterns.

Journal of Ethnopharmacology (2008)

One of the most precise mechanistic findings in the field: ibogaine inhibits serotonin reuptake not by sitting in the transporter's binding site (as SSRIs do) but by stabilizing the entire transporter protein in an inward-facing conformation. This essentially locks it closed. This noncompetitive mechanism is distinct from any other antidepressant on the market. It contributes to ibogaine's antidepressant-like effects and may partly explain the sustained mood improvements many patients report long after ibogaine has cleared their system. The paper gave researchers a clear molecular target for one component of ibogaine's broad pharmacological profile.

Researchers published a systematic analysis of ibogaine's cardiac effects, specifically its ability to prolong the QT interval, a measure of cardiac electrical activity that, when extended, can increase the risk of dangerous arrhythmias. This paper formalized the cardiac safety concern that now drives the requirement for pre-treatment cardiac screening, magnesium co-administration, and continuous ECG monitoring in medically supervised ibogaine programs.

Drug and Alcohol Dependence (2008)

New Zealand researchers Geerte Noller and colleagues conducted an observational study with 14 heroin-dependent individuals who received ibogaine treatment. At three-month follow-up, the majority reported significantly reduced cravings and sustained reductions in use, with several reporting full abstinence. The study contributed to the growing non-US evidence base and helped establish New Zealand as a significant site of ibogaine research.

Journal of Psychoactive Drugs (2012)

Eduardo Ekman Schenberg, Bruno Rasmussen Chaves, and colleagues published a retrospective analysis of 75 patients with alcohol, cannabis, cocaine, and crack dependence who received ibogaine-assisted therapy in Brazil. The results were striking: 61% achieved abstinence over five months. Patients treated once reported a median abstinence period of 5.5 months; those treated multiple times, 8.4 months, statistically significant improvements over pre-treatment baselines. No serious adverse reactions or fatalities were observed. Brazil's unregulated status for ibogaine at the time allowed this work to proceed where US and European researchers could not go, and it established Brazil's clinical research community as a serious contributor to the field.

The paper that put ibogaine's cardiac risk on solid mechanistic ground. Thurner and colleagues showed that ibogaine (and noribogaine) block the hERG potassium channel, the same channel involved in drug-induced arrhythmias across the pharmaceutical industry. When hERG is blocked, cardiac repolarization slows and the QT interval extends. Extend it far enough and the risk of torsades de pointes, a potentially fatal arrhythmia, rises sharply. This paper is why every competent ibogaine program now requires baseline ECG measurement, corrected QT interval screening, and continuous cardiac monitoring during treatment. The risk is real, mechanistically understood, and manageable under proper medical supervision.

Researcher Alan K. Davis and colleagues surveyed 88 individuals with opioid use disorder who had received ibogaine treatment. At 12-month follow-up, participants reported significant and sustained reductions in opioid use, craving, and depression scores. The study is notable for its sample size and long follow-up window: most ibogaine studies tracked outcomes for 30 days or less.

Journal of Psychoactive Drugs (2017)

A follow-up to the 2014 Brazilian retrospective, this qualitative study explored what 22 patients with substance use disorders actually experienced during their ibogaine treatments, and what those experiences meant to them therapeutically. Using interpretive phenomenological analysis, Eduardo Schenberg, Bruno Rasmussen Chaves, and colleagues found that patients reported decreased craving, improved personal relationships, better quality of life, and stronger self-efficacy. This study matters because it takes the subjective experience seriously as therapeutic content rather than a side effect to be minimized, a frame that has since become central to how ibogaine research integrates phenomenology with clinical outcome measurement.

The strongest medium-term observational dataset from New Zealand, where ibogaine is regulated. Fourteen opioid-dependent New Zealanders were followed for 12 months after ibogaine treatment. Drug use scores and depression scores fell significantly and held through follow-up. One patient died during treatment, a fact the authors reported transparently and without minimizing. That combination of genuine therapeutic signal and documented fatality is exactly the tension that defines responsible ibogaine research: the compound appears to work, it can also kill, and the only defensible path forward is rigorous medical management. This paper argued both sides of that equation with unusual honesty.

One of the most carefully designed observational studies of ibogaine for opioid dependence, conducted at a clinical site in Mexico. Thirty patients received ibogaine (mean total dose approximately 1,540mg ± 920mg). Withdrawal scores fell by roughly 76% within 72 hours. At one-month follow-up, half the cohort reported no opioid use in the prior 30 days. ASI drug-use and related life-area scores improved through the follow-up period. These numbers come from an uncontrolled observational study, not a randomized trial, but they are prospectively collected, clinically significant, and hard to explain away. They represent some of the strongest human outcome data available for ibogaine in opioid dependence.

Deborah Mash published comprehensive pharmacokinetics and safety data from 191 patients treated at the St. Kitts program over a 14-year period, the longest and largest single-site safety dataset in ibogaine history at the time. The analysis documented the incidence of adverse events, the cardiac risk profile, and the relationship between noribogaine plasma levels and treatment outcomes.

Frontiers in Pharmacology (2018)

A significant number of patients in ibogaine treatment report experiences that score on standardized measures of 'complete mystical experience', and those who do tend to have better outcomes. This study analyzed the phenomenological content of ibogaine treatments in an opioid treatment cohort at a Mexico-based clinic and found that reports of insight, guilt resolution, spiritual transformation, and emotional release were common, and correlated with better addiction outcomes and psychological functioning at follow-up. The findings connect ibogaine to a broader literature on the role of meaning-making in psychedelic-assisted healing and raise the question of whether the visionary experience is incidental to the treatment or central to it.

A retrospective survey of 51 Special Operations veterans who received a combined ibogaine and 5-MeO-DMT program at a clinical site in Mexico. Self-reported reductions in PTSD symptoms, depression, anxiety, suicidality, cognitive impairment, and functional disability were large across the board. The main caveat: this is a combined-intervention retrospective study. Effects cannot be attributed to ibogaine alone. But as program-evaluation data for an approach that was treating a population with very limited other options, the numbers are hard to ignore. The study was a direct precursor to the Stanford Nature Medicine trial, providing preliminary evidence that drove more rigorous follow-up research.

David Olson's lab at UC Davis published work on Tabernanthalog (TBG), a synthetic analogue of ibogaine engineered to retain its therapeutic effects while eliminating its hallucinogenic properties and reducing cardiac risk. In animal models, TBG showed antidepressant effects and reduced ethanol and heroin consumption after a single dose, without the extended duration or psychedelic experience of ibogaine itself. The work opened a new direction in ibogaine-derived drug development.

The most rigorously monitored open-label safety study in the ibogaine literature. Fourteen opioid-dependent patients in the Netherlands received 10mg/kg ibogaine under intensive cardiac and neurological monitoring. Every patient developed severe but temporary ataxia. Half exceeded a corrected QT of 500ms, a threshold that routinely triggers caution in cardiology. Yet no patient developed torsades de pointes, and 11 of 14 remained off morphine for the 24-hour observation window. The study confirmed that the cardiac risk is real and quantifiable, while also showing it is manageable with appropriate protocols. A companion PK/PD analysis showed that CYP2D6 activity strongly predicted ibogaine clearance. The same dose hits different people very differently.

The first trial of ibogaine ever run to full Good Clinical Practice standards. After approval from the UK medicines regulator (MHRA) in 2021, DemeRx and atai Life Sciences began dosing at MAC Clinical Research in Manchester that September. The design is a two-stage Phase 1/2a: single oral doses in around 30 healthy volunteers first, then, after a regulatory review of the accumulated safety data, treatment of around 80 opioid-dependent patients. Cardiac monitoring sits at the center of the protocol, a direct response to ibogaine's known hERG and QT liabilities. The program is the foundation for a planned combined Phase 2/3, which would be the first late-stage regulatory trial in ibogaine's history.

Psychologist Bruno Ramos Gomes, who has treated over 400 patients with ibogaine in Brazil since 2010, and public health researcher Luis Fernando Tofoli conducted an ethnographic study of four ibogaine treatment clinics in Brazil, exploring how practitioners and patients understand the medicine's mechanism and effects. The study sits at the intersection of clinical observation and medical anthropology, documenting how ibogaine is gaining ground in Brazilian drug treatment because of its effectiveness against withdrawal symptoms, and how providers navigate the tension between its neurological effects and its spiritual dimensions. Brazil's unregulated status made this kind of naturalistic clinical observation possible in ways it would not have been elsewhere.

The prospective follow-up to the 2020 retrospective survey, and a substantially stronger dataset. Eighty-six trauma-exposed Special Operations veterans received sequential ibogaine and 5-MeO-DMT with psychotherapeutic support at a clinical program in Mexico. Improvements were large across PTSD, depression, anxiety, insomnia, post-concussive symptoms, life satisfaction, and cognitive functioning, with early signals that the gains held at six months. A companion analysis of 45 participants with concurrent risky drinking found alcohol consumption dropped and stayed down at six months, and the veterans whose drinking improved also showed the biggest PTSD gains. The caveats have not moved: open-label, uncontrolled, a highly selected population, and a combined protocol, so none of this can be attributed to ibogaine alone.

A landmark study from the Stanford Psychedelic Science Initiative treated 30 special operations military veterans with ibogaine and magnesium at a clinical facility in Mexico. At one-month follow-up, participants showed dramatic improvements in PTSD symptoms, depressive symptoms, anxiety, and functional disability. Cognitive function scores also improved significantly. Published in Nature Medicine in January 2024, it was the first rigorously conducted study of ibogaine for PTSD and traumatic brain injury in humans, and it generated mainstream scientific and policy attention that accelerated clinical development globally.

A new family of ibogaine analogues built around a benzofuran core rather than the natural indole. In rodent models, oxa-iboga compounds disrupted opioid self-administration at least as effectively as ibogaine itself, without measurable activity at the hERG cardiac channel that makes ibogaine dangerous. They join a widening field of engineered iboga compounds, alongside Olson's tabernanthalog and Glick and Kuehne's 18-methoxycoronaridine (now named zolunicant), each attempting the same trade: keep the therapeutic signal, lose the cardiac liability. All of this remains animal work. Whether any analogue reproduces ibogaine's effects in humans, and whether losing pieces of its messy polypharmacology costs durability, are open questions.

Nature Communications, 2024;15:8118

The most rigorous pharmacokinetic study of ibogaine in patients to date, from the same Dutch consortium behind the 2021 safety study. Fourteen opioid-dependent patients received a single 10mg/kg dose of pharmaceutical-grade ibogaine under full monitoring. The findings turned cardiac risk from a warning into a curve: QT prolongation tracked ibogaine blood levels, not noribogaine, with a modeled maximum of roughly 68ms. Ataxia tracked ibogaine concentration the same way. And the CYP2D6 enzyme dominated everything: activity scores had a highly significant effect on how fast people cleared the drug, and these 14 patients alone spanned poor, intermediate, extensive, and ultra-rapid metabolizers. The same dose is not the same dose. The authors argue this is the empirical basis for genotype-guided dosing in future trials.

One of the most important safety papers in recent ibogaine literature: a 10-year retrospective case series from the UK National Poisons Information Service. Seven patients presented to poison control following ibogaine exposure. Six had cardiotoxic features. Common findings included cardiac arrest, QT prolongation, torsades de pointes, bradycardia, coma, convulsions, and vomiting. Every single case was symptomatic on presentation. The series is small, seven patients over a decade, and it is not incidence data. But it moves ibogaine toxicity from isolated case reports to a documented pattern of recurrent severe events in real-world uncontrolled use. It is the clearest current argument for why medical supervision is not optional.

A possible answer to the question that hangs over every ibogaine outcome study: why do the effects outlast the drug? In adult mice, a single dose of ibogaine restored a form of cortical plasticity normally locked to a juvenile critical period of development. The mechanism was visible in the tissue: roughly 30% reductions in perineuronal nets, the molecular scaffolding that stabilizes adult brain circuits, and a loosening of inhibition in the cortex. In plain terms, the adult brain briefly became rewirable in a way it usually is not. This is one preprint, in mice, in the visual cortex, and it has not yet passed peer review. But it gives the durability of ibogaine's clinical effects a concrete candidate mechanism rather than a shrug.

Two multiple sclerosis patients treated with ibogaine at a clinic in Mexico underwent serial MRI scans. One, a 41-year-old man with relapsing-remitting MS, showed a 70% reduction in lesion volume at three months, with diffusion changes consistent with remyelination and reduced inflammation. The second showed structural changes in regions tied to pain and emotional processing. Two patients, one clinic, no blinding: this proves nothing on its own. What makes it worth recording is that it is the first human imaging data to connect ibogaine to the remyelination signal that animal studies had already hinted at.

The first structural MRI evidence of brain change after ibogaine treatment in humans, drawn from the same 30 Stanford MISTIC veterans. About a week after magnesium-ibogaine treatment, cortical thickness had increased in 11 of 13 brain regions measured, and the changes held at one month. Machine-learning estimates of brain age dropped by 1.6 years. The usual limits apply: a small cohort, no control group, and results reported so far as a conference abstract. But it moves the neurotrophic story, that ibogaine promotes structural repair rather than just symptom relief, from animal data and theory into human measurement.

In May 2025, Texas enacted Senate Bill 2308 and House Bill 3717, putting $50 million of state money behind FDA-approved clinical trials of ibogaine for substance use disorder, trauma-related conditions, and traumatic brain injury. It is the largest publicly funded psychedelic research initiative any government has undertaken. The state chose UTHealth Houston, with the University of Texas Medical Branch at Galveston, to lead a multi-institution consortium called IMPACT. The politics behind it are telling: an earlier attempt to fund ibogaine research from opioid settlement money in Kentucky was blocked in 2023. Two years later, a much larger program passed a state legislature. The question of whether ibogaine deserves rigorous trials has stopped being fringe.

Texas Senate Bill 2308 and House Bill 3717, 89th Legislature (2025)

A mechanistic follow-up to the Stanford Nature Medicine veteran study, this paper asked what magnesium-ibogaine therapy actually does to the brain. In 30 combat veterans with TBI, resting-state EEG was measured before treatment, 3.5 days after, and one month later. Slower-frequency power increased; faster-frequency power decreased; peak alpha frequency and neural complexity both fell. Several of these EEG markers correlated with improvements in PTSD symptoms, anxiety, and executive function. This suggests the neurophysiological changes are not random but tied to the clinical outcomes. Published in Nature Mental Health, the study is among the first to link ibogaine treatment to measurable changes in human brain dynamics, adding biological depth to what had previously been self-report data.

Every dramatic one-month result raises the same question: does it hold? The Stanford team tracked the 30 MISTIC veterans out to a full year after their magnesium-ibogaine treatment, the longest structured follow-up of this cohort. The paper is a preprint still under review, so the numbers are not final and we are not quoting them here. What matters is that the durability question, the single biggest gap between ibogaine's striking short-term data and its clinical credibility, is now being answered with a prospective dataset rather than anecdote.

On April 18, 2026, a US executive order directed expanded federal coordination on the evaluation of psychedelic compounds, including ibogaine, for severe mental illness and conditions affecting military veterans. It committed $50 million in ARPA-H funding to psychedelic research, expanded right-to-try pathways for ibogaine, and directed the FDA to issue priority review vouchers. The FDA commissioner subsequently said late-stage trial data could be reviewed within one to two months of submission rather than the standard year. Combined with the Texas program, this puts roughly $100 million of US public money behind a compound that federal agencies had walked away from in 1995. None of it changes the evidence base by itself. It changes how fast the evidence can now be built.

Executive order of April 18, 2026; summarized in the MAPS Ibogaine Investigator's Brochure, 2026, p. 29

The largest ibogaine safety dataset ever assembled, and the first to ask where the risk actually lives. Arns, Shinozuka, and Barsuglia gathered treatment records from 11 international clinics operating under the 2016 safety guidelines: 19,071 patients in total. Six died within 72 hours of dosing, a rate of 0.03%, and every one of them was an opioid detox patient. Among 8,689 people treated for PTSD, trauma, and other non-addiction indications, there were no deaths. An updated systematic review of every documented fatality since 1990 showed the same pattern: 41 of the 44 deaths with a known indication involved substance use disorder, predominantly opioid detox. The caveats are real. This is a preprint that has not completed peer review, the authors describe the 0.03% as a lower bound because clinics reported their own outcomes, and one author holds equity in ibogaine companies (he was firewalled from the data analysis). Even so, it retires a number the field had been repeating for two decades: the famous 1-in-427 death rate was derived from 1989–2006 data, before modern cardiac screening existed. The risk was never evenly spread. It is cardiac, it concentrates in opioid detoxification, and it is exactly what ECG screening and hospital monitoring exist to manage.